{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:30:01Z","timestamp":1786645801207,"version":"build-2736575974"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K12742"],"award-info":[{"award-number":["JP25K12742"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K12647"],"award-info":[{"award-number":["JP24K12647"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reduced skeletal muscle mass may impair outcomes of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma. We evaluated whether temporal muscle thickness (TMT) on routine head computed tomography was associated with treatment response and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 109 patients treated with nivolumab or pembrolizumab between 2017 and 2023 (89 men [81.7%], 20 women [18.3%]; median age 69 years [range 21\u201388]). TMT was measured on CT images at the level where the Sylvian fissure was most clearly visualized, perpendicular to the temporalis muscle long axis, on both sides, and the mean of the bilateral values was used. Sex-specific cutoffs were defined by time-dependent receiver operating characteristic analysis for 12-month overall survival (5.53 mm for men; 3.92 mm for women). Associations with objective response and survival were assessed using logistic regression and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Objective response was evaluable in 105 patients (complete response 12, partial response 30, stable disease 18, progressive disease 45), yielding a response rate of 40.0% and a disease control rate of 57.1%. High temporal muscle thickness was associated with response (univariable odds ratio 2.64, 95% confidence interval 1.18\u20135.90; p\u2009=\u20090.018) and remained significant after adjustment for chemotherapy (adjusted odds ratio 2.42, 95% confidence interval 1.05\u20135.58; p\u2009=\u20090.038). One-year progression-free survival was 36.5% in the high group versus 15.8% in the low group (absolute difference 20.7%; p\u2009=\u20090.010; adjusted hazard ratio 0.57, 95% confidence interval 0.36\u20130.90; p\u2009=\u20090.017). One-year overall survival was 73.1% versus 47.4% (absolute difference 25.7%; p\u2009=\u20090.001; adjusted hazard ratio 0.54, 95% confidence interval 0.34\u20130.86; p\u2009=\u20090.010).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Temporal muscle thickness, obtainable from routine head computed tomography, was independently associated with response and survival in patients receiving immune checkpoint inhibitors and may serve as a practical host-related imaging marker for prognostic risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0356013","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:38:16Z","timestamp":1786642696000},"page":"e0356013","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal muscle thickness is associated with immunotherapy outcomes in head and neck squamous cell carcinoma"],"prefix":"10.1371","volume":"21","author":[{"given":"Hirotaka","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-1038","authenticated-orcid":true,"given":"Kiyohito","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Inohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"10","key":"pone.0356013.ref001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3109\/00016489.2014.906750","article-title":"Factors associated with malnutrition in patients with head and neck cancer","volume":"134","author":"Y Takenaka","year":"2014","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"pone.0356013.ref002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","article-title":"GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community","volume":"38","author":"T Cederholm","year":"2019","journal-title":"Clin Nutr"},{"issue":"1","key":"pone.0356013.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"pone.0356013.ref004","doi-asserted-by":"crossref","first-page":"106018","DOI":"10.1016\/j.oraloncology.2022.106018","article-title":"Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study","volume":"132","author":"Y Takenaka","year":"2022","journal-title":"Oral Oncol"},{"key":"pone.0356013.ref005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.oraloncology.2016.09.006","article-title":"Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients","volume":"62","author":"JE Swartz","year":"2016","journal-title":"Oral Oncol"},{"key":"pone.0356013.ref006","doi-asserted-by":"crossref","first-page":"105558","DOI":"10.1016\/j.oraloncology.2021.105558","article-title":"Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer","volume":"122","author":"SI Bril","year":"2021","journal-title":"Oral Oncol"},{"issue":"1","key":"pone.0356013.ref007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/1078-0432.CCR-21-1987","article-title":"Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials","volume":"28","author":"J Furtner","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pone.0356013.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207849","article-title":"High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases","volume":"13","author":"J Leitner","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"pone.0356013.ref009","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1007\/s10147-024-02591-3","article-title":"Prognostic value of pretreatment temporal muscle thickness after curative surgery for oral cavity squamous cell carcinoma","volume":"29","author":"T Mukai","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"pone.0356013.ref010","doi-asserted-by":"crossref","first-page":"19717","DOI":"10.1038\/s41598-021-99201-3","article-title":"Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma","volume":"11","author":"B Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0356013.ref011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"pone.0356013.ref012","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/00016489.2023.2288910","article-title":"Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors","volume":"143","author":"N Miyamoto","year":"2023","journal-title":"Acta Otolaryngol"},{"key":"pone.0356013.ref013","doi-asserted-by":"crossref","first-page":"941254","DOI":"10.3389\/fimmu.2022.941254","article-title":"Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors","volume":"13","author":"PP Chong","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0356013.ref014","doi-asserted-by":"crossref","first-page":"2215543","DOI":"10.1080\/07853890.2023.2215543","article-title":"The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: an umbrella meta-analysis of randomized controlled trials","volume":"55","author":"D Hu","year":"2023","journal-title":"Ann Med"},{"key":"pone.0356013.ref015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s43094-025-00804-8","article-title":"Current perspectives on malnutrition and immunomodulators bridging nutritional deficiencies and immune health","volume":"11","author":"A Majumdar","year":"2025","journal-title":"Futur J Pharm Sci"},{"issue":"10","key":"pone.0356013.ref016","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hed.23785","article-title":"Prognostic significance of body mass index before treatment for head and neck cancer","volume":"37","author":"Y Takenaka","year":"2015","journal-title":"Head Neck"},{"issue":"10","key":"pone.0356013.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259288","article-title":"Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis","volume":"16","author":"Y Takenaka","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"pone.0356013.ref018","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/hed.26716","article-title":"Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients","volume":"43","author":"A Hoesseini","year":"2021","journal-title":"Head Neck"},{"issue":"5","key":"pone.0356013.ref019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Y Takenaka","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"pone.0356013.ref020","doi-asserted-by":"crossref","first-page":"112077","DOI":"10.1016\/j.nut.2023.112077","article-title":"Prognostic value of temporal muscle thickness, a novel radiographic marker of sarcopenia, in patients with brain tumor: A systematic review and meta-analysis","volume":"112","author":"Y-W Yang","year":"2023","journal-title":"Nutrition"},{"issue":"7","key":"pone.0356013.ref021","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jjco\/hyae042","article-title":"Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab","volume":"54","author":"Y Takenaka","year":"2024","journal-title":"Jpn J Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:38:19Z","timestamp":1786642699000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356013"}},"subtitle":[],"editor":[{"given":"Satyajeet","family":"Rath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356013","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}